Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
Public ClinicalTrials.gov record NCT00056641. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, Randomized, Parallel-group Pharmacokinetics Trial of Tipranavir / Ritonavir (TPV/RTV), Alone or in Combination With RTV-boosted Saquinavir (SQV), Amprenavir (APV), or Lopinavir (LPV), Plus an Optimized Background Regimen, in Multiple Antiretroviral (ARV) Experienced Patients.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, randomized, parallel group pharmacokinetics trial of tipranavir/ritonavir (TPV/RTV), alone or in combination with RTV-boosted saquinavir (SQV), amprenavir (APV) or lopinavir (LPV), plus an optimized background regimen, in multiple antiretroviral (ARV) experienced HIV-1 patients. The primary objective is to determine the safety and pharmacokinetics of: TPV/RTV given with an optimized background regimen (OBR) and TPV/RTV given in combination with saquinavir, amprenavir, or Kaletra® and an optimized background regimen (OBR).
Study identification
- NCT ID
- NCT00056641
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 328 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 18, 2003 (Actual)
- Primary completion
- Jan 27, 2004 (Actual)
- Completion
- Not listed
- Last update posted
- Dec 1, 2023
Started 2003
United States locations
- U.S. sites
- 34
- U.S. states
- 16
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| Boehringer Ingelheim Investigational Site | Berkeley | California | — | — |
| Boehringer Ingelheim Investigational Site | Fountain Valley | California | — | — |
| Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| Boehringer Ingelheim Investigational Site | San Francisco | California | — | — |
| Kaiser Permanente Medical Center | San Francisco | California | — | — |
| San Francisco VAMC | San Francisco | California | — | — |
| Boehringer Ingelheim Investigational Site | Norwalk | Connecticut | — | — |
| Washington DC VA Medical Center | Washington D.C. | District of Columbia | — | — |
| North Broward Hospital District | Fort Lauderdale | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Fort Myers | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Sarasota | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Vero Beach | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| Mercer University School of Medicine | Macon | Georgia | — | — |
| University of Kentucky Medical Center | Lexington | Kentucky | — | — |
| Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| Brigham and Women's Hospital | Boston | Massachusetts | — | — |
| Boehringer Ingelheim Investigational Site | Springfield | Massachusetts | — | — |
| Henry Ford Hospital | Detroit | Michigan | — | — |
| Boehringer Ingelheim Investigational Site | Santa Fe | New Mexico | — | — |
| Albany Medical College | Albany | New York | — | — |
| Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| University of New York, Stony Brook | Stony Brook | New York | — | — |
| Duke University Medical Center | Durham | North Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Huntersville | North Carolina | — | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | — | — |
| UT Southwestern | Dallas | Texas | — | — |
| Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| Boehringer Ingelheim Investigational Site | Annandale | Virginia | — | — |
| Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 75 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00056641, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 1, 2023 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00056641 live on ClinicalTrials.gov.